Skip to main content

Table 3 Biodistribution for nano-carrier 188Re-liposome in normal organs of patients (n = 12)

From: A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors

Normal organ

Time point

(%ID/kg)

1 h

8 h

24 h

48 h

72 h

Lungs

9.4 ± 2.3

7.5 ± 2.7

6.8 ± 2.6

3.7 ± 2.2

2.2 ± 1.4

Liver

14.7 ± 5.4

12.6 ± 4.9

11.2 ± 4.7

8.7 ± 4.4

5.9 ± 4.5

Heart contents

4.2 ± 1.9

3.1 ± 1.8

2.7 ± 1.4

1.4 ± 1.1

0.7 ± 0.5

Spleen

13.2 ± 8.0

12.3 ± 8.3

11.4 ± 7.3

9.0 ± 7.0

6.3 ± 6.3

Kidneys

8.1 ± 5.8

6.1 ± 2.5

5.7 ± 2.5

3.7 ± 1.5

2.1 ± 2.0

Muscle

0.4 ± 0.3

0.2 ± 0.3

0.1 ± 0.2

0.1 ± 0.1

0.1 ± 0.1

  1. Data is expressed as a percentage of injected activity per kilogram (%ID/kg) ± SD